Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
BlueRock and Foundation Fighting Blindness Partner for IRD Study
BlueRock Therapeutics LP, a clinical-stage cell therapy company and a subsidiary of Bayer, in partnership with Foundation Fighting Blindness, has announced their collaboration to introduce a new cohort to the Foundation’s ‘Uni-Rare natural history study’. This initiative focuses on individuals…
Nanodropper Adaptor Proven Effective in IOP Management
In a pivotal development in the field of ophthalmology, Nanodropper Inc announced that the results from a clinical trial evaluating the Nanodropper® Adaptor have been published in the esteemed journal, Ophthalmology. The study’s findings indicate that there was no clinically…
Scientists Create Enzyme-Activated Healing Contact Lenses
Scientists at the University of Waterloo have made a groundbreaking development in eye care technology by creating a new type of contact lens that not only serves as a protective bandage for corneal wounds but also delivers healing drugs in…
Gene Therapy Aims to Curtail Retinal Degeneration in RP
In a landmark study that promises new hope for nearly 1.5 million people worldwide suffering from retinitis pigmentosa (RP), scientists at Columbia University Vagelos College of Physicians and Surgeons are pioneering a gene therapy that could potentially treat RP patients…
Minocycline Fails to Halt Progression of Dry AMD
In a recent phase II clinical trial conducted by the National Eye Institute (NEI), part of the National Institutes of Health, the antibiotic minocycline, known for its anti-inflammatory properties, was tested for its efficacy in slowing down the progression of…
Purdue Engineering Team to Develop Smart Contact Lenses
Research teams at Purdue University’s College of Engineering have been awarded two grants from the National Eye Institute, totaling an impressive $6.7 million. These funds are earmarked for the development of specialized smart soft contact lenses designed for the continuous monitoring…
Nicox Reveals Successful Phase 3 Glaucoma Eye Drop
Nicox SA announced the results of its pivotal Mont Blanc Phase 3 trial, which compared the efficacy of its novel nitric oxide-donating bimatoprost eye drop, NCX 470, against latanoprost in reducing intraocular pressure (IOP) in patients suffering from open-angle glaucoma…
Innovent’s nAMD Drug Succeeds in Phase 2 Trial
Innovent Biologics announced that its second Phase 2 clinical trial of efdamrofusp alfa (R&D code: IBI302), a high-dose recombinant human VEGFR-Fc-Human CR1 fusion protein injection, has achieved its primary endpoint in treating Chinese subjects with neovascular age-related macular degeneration (nAMD).…
Beyond Appearance: The Health Implications of Eye Color
Eye color, a key trait that contributes to the uniqueness of an individual’s appearance, is determined by multiple genetic factors and can signify more than just aesthetic differences. It involves the complex interplay of genetics, melanin distribution in the iris,…
2023 Recap: Top 20 Ophthalmic Collaborations of the Year
As we bid farewell to 2023, it’s time to reflect on the remarkable collaborations that have shaped the landscape of ophthalmic innovation. The past year witnessed groundbreaking partnerships between pharmaceutical giants, tech innovators, and research institutions, all aimed at advancing…